Welcome to DailyUpdates Cardiovascular disorders - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 2 more day(s). To receive DailyUpdates by e-mail register here

PubMed DailyUpdates: Breaking Scientific Publications for the Drug Discovery Community

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Cardiovascular disorders

If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work


Today's journal articles

No journal articles today

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

A Study of Once-Weekly Emicizumab in Children and Adolescents With Hemophilia A and Factor VIII (FVIII) Inhibitors

Previous Journal Entries

Collagen-induced arthritis increases inducible nitric oxide synthase not only in aorta but also in the cardiac and renal microcirculation of mice.

Enhanced Platelet Toll-like Receptor 2 and 4 Expression in Acute Coronary Syndrome and Stable Angina Pectoris.

Anti-platelet effects of nimesulide in isoproterenol-induced myocardial ischaemia and infarction in rabbits.

Association of pentraxin-3 with the severity of rheumatic mitral valve stenosis.

The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice.

TRAM-34 attenuates hypoxia induced pulmonary artery smooth muscle cell proliferation.

Effect of a novel peptide, WKYMVm- and sirolimus-coated stent on re-endothelialization and anti-restenosis.

Cardioprotective Actions of Tgfβri Inhibition Through Stimulating Autocrine/Paracrine of Survivin and Inhibiting Wnt in Cardiac Progenitors.

Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development.

Qualitative and quantitative pharmacophore-similarity assessment of anthranilamide-based factor Xa inhibitors: applications on similar molecules with identical biological endpoints.


A Novel Ligustrazine Derivative T-VA Prevents Neurotoxicity in Differentiated PC12 Cells and Protects the Brain against Ischemia Injury in MCAO Rats.

Endothelial Cell Apoptosis Induces TGF-β Signaling-Dependent Host Endothelial-Mesenchymal Transition to Promote Transplant Arteriosclerosis.

Discovery and optimization of novel, selective histone methyltransferase SET7 inhibitors by pharmacophore - and docking - based virtual screening.

Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis.

Non-β-blocking R-carvedilol enantiomer suppresses Ca2+ waves and stress-induced ventricular tachyarrhythmia without lowering heart rate or blood pressure.

Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial.

The Effect of a Selective Inhibitor of Phosphodiesterase-9 on Oxidative Stress, Inflammation and Cytotoxicity in Neutrophils from Patients with Sickle Cell Anaemia.

Effects of the Factor Xa Inhibitor, Fondaparinux, on the Stability of Atherosclerotic Lesions in Apolipoprotein E-Deficient Mice.

Today's News Items


Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb Ischemia

Training Courses & Meetings

No events listed

Previous News Items

Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and Rare Bleeding Disorders

Spark Therapeutics and Pfizer Announce Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity

CSL Behring Presents Phase III Data for IDELVION for Hemophilia B at the World Federation of Hemophilia 2016 World Congress

CSL Behring Presents Pivotal Efficacy Data for AFSTYLA In Adolescents and Children with Hemophilia A at the World Federation of Hemophilia 2016 World Congress

Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency